5 assets in Dedifferentiated Liposarcoma

Therapeutic assets addressing Dedifferentiated Liposarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- Dedifferentiated Liposarcoma	STORM Therapeutics LTD	P1/2	CC (47)
Stc-15 Dedifferentiated Liposarcoma	STORM Therapeutics LTD	P1/2	CC (47)
Toripalimab Dedifferentiated Liposarcoma	STORM Therapeutics LTD	P1/2	CC (47)
okn4395 Dedifferentiated Liposarcoma	Epkin	P1	CC (43)
Pembrolizumab Dedifferentiated Liposarcoma	Epkin	P1	CC (43)